A small U.S. company has productively redeveloped stimulated hair and skin growth in pigs with abrasions and burns, making the way for a scientific burst through that might result to the rebirth of completely operational human skin.
Located in Salt Lake City, the patented method to tissue engineering by PolarityTE Inc. is developed to utilize own healthy tissue of a patient to re-produce human skin for the cure of wounds and burns.
In spite of current improvements in regenerative surgery, surgeons and doctors cannot offer burn victims what they need the most—their skin.
“Present methods to cure severe burns are “extremely limited” in their efficiency and in some cases, are rather costly,” Denver Lough, PolarityTE’s CEO and founder, said to the media.
Epicel, a skin splice extensively employed in burn units and is traded by Massachusetts, Cambridge-based Vericel Corp., does not lead in fully functional and thick skin, which is the main objective of PolarityTE.
PolarityTE performed its pre-clinical research on injured pigs in Utah at an animal facility. “The utilization of therapy led in growth of hair follicles, scar-less healing, the progressive regeneration of all skin layers, and complete wound coverage,” the company claimed.
Since pig’s skin is more robust and complex as compared to human skin, victorious swine information is characteristically viewed as a forerunner to efficiency in human tests.
PolarityTE anticipates beginning a human test shortly this year and the cell treatment might hit the industry in twelve to eighteen months after that, claimed Lough, who worked at Johns Hopkins Hospital as Senior Plastic Surgery Resident before creating PolarityTE in 2016.
“If clinically victorious, the PolarityTE platform can give the initial scientific burst through in reconstructive surgery and wound healing in nearly 50 years of history,” Lough said.
The technology also has the probability to design fully operational tissues, comprising muscle, bone, liver, and the cartilage, PolarityTE claimed.
The firm said that it would be challenging and tough fund next test and it also refused to give details.
PolarityTE is supported by pharmacy industry expert Phil Frost, presently Chief Executive of OPKO Health Inc., and a small number of various industry executives as well.